Skip to content
Movantik, Moventig(naloxegol)
Movantik, Moventig (naloxegol) is a small molecule pharmaceutical. Naloxegol was first approved as Movantik on 2014-09-16. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation and opioid-related disorders.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Movantik
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Naloxegol oxalate
Tradename
Company
Number
Date
Products
MOVANTIKVALINORN-204760 RX2014-09-16
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
movantikNew Drug Application2023-03-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
constipationHP_0002019D003248K59.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Naloxegol Oxalate, Movantik, Valinor
90124692032-04-02DS, DP
77861332028-09-16DS, DP
80674312024-12-16U-1185
70565002024-06-29DPU-1185
ATC Codes
A: Alimentary tract and metabolism drugs
— A06: Drugs for constipation
— A06A: Drugs for constipation
— A06AH: Peripheral opioid receptor antagonists
— A06AH03: Naloxegol
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Opioid-induced constipationD0000796891151614
ConstipationD003248HP_0002019K59.03223—9
NeoplasmsD009369C80———112
PainD010146EFO_0003843R52———1—1
Postoperative painD010149G89.18———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Critical illnessD016638——1——1
Brain injuriesD001930S06.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C67—1———1
Non-small-cell lung carcinomaD002289—1———1
GastroparesisD018589EFO_1000948K31.84—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
Biological availabilityD0016822————2
Renal insufficiencyD051437HP_0000083N191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNALOXEGOL
INNnaloxegol
Description
Naloxegol is an organic heteropentacyclic compound that is naloxone in which the keto group is replaced by a PEG moiety. Used for treatment of opioid-induced constipation. It has a role as a mu-opioid receptor antagonist and a cathartic. It is an organic heteropentacyclic compound, a member of phenols, an aromatic ether, a tertiary alcohol and a polyether. It is functionally related to a naloxone. It derives from a hydride of a morphinan.
Classification
Small molecule
Drug classnarcotic agonists/antagonists (normorphine type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5
Identifiers
PDB—
CAS-ID854601-70-0
RxCUI1551777
ChEMBL IDCHEMBL2219418
ChEBI ID82975
PubChem CID56959087
DrugBankDB09049
UNII ID44T7335BKE (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Movantik - RedHill Biopharma
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Movantik - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 346 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
164 adverse events reported
View more details